Matches in SemOpenAlex for { <https://semopenalex.org/work/W2897846549> ?p ?o ?g. }
Showing items 1 to 87 of
87
with 100 items per page.
- W2897846549 endingPage "viii212" @default.
- W2897846549 startingPage "viii212" @default.
- W2897846549 abstract "Background: Multimodality treatments of patients with esophageal adenocarcinoma (EAC) improve survival, but the optimal treatment strategy remains undetermined. This study aimed to compare response, local recurrence and survival outcomes in patients undergoing neoadjuvant paclitaxel and carboplatin chemoradiotherapy with 41Gy (CROSS) with neoadjuvant cisplatin and 5-fluoruracil (CF)-based chemoradiotherapy with 45Gy (CFRT) or CF chemotherapy followed by oesophagectomy for EAC. Methods: Patients who underwent CROSS, CFRT or CF followed by surgery for EAC were identified from two single institution prospective databases from Australia and the Netherlands (2000-2018) and included in this study. After pair-wise propensity score matching (caliper 0.2) using pre-treatment variables (age, gender, year of treatment, tumor length and site, and clinical T stage), we compared the impact of the treatments on pathological outcomes, patterns of recurrence and overall survival. Results: Of the 637 eligible patients, 429 patients were analysed following propensity score matching. This resulted in 143 patients in each group with median follow up 61 months. CROSS and CFRT demonstrated significantly higher pathological complete response rates (p < 0.001), lower ypT stage (p < 0.001) and lower ypN stage (p < 0.001) compared with CF. There were no statistically significant differences in 5-year local recurrence-free survival between the three treatment groups: CROSS 76% (95%CI: 68-85); CFRT 71% (95%CI: 64-81); and CF 66% (95%CI: 65-76). Similarly, there were no significant differences in 5-year overall survival rates between groups: CROSS 52% (95%CI: 44-62); CFRT 40% (95%CI: 32-49); and 46% (95%CI: 38-55)(p = 0.18, log rank). Median overall survival for CROSS was 69 months (95%CI: 47-139), for CFRT 32 months (95%CI: 26-52), and for CF 47 months (95%CI: 33-66) (p = 0.33, log rank). Conclusions: In this study, there were higher pathological response rates and lower pathological stage associated with CROSS and CFRT. However, overall survival and local recurrence was similar for CROSS, CF and CFRT. Legal entity responsible for the study: The University of Queensland. Funding: Has not received any funding. Disclosure: All authors have declared no conflicts of interest." @default.
- W2897846549 created "2018-10-26" @default.
- W2897846549 creator A5005797468 @default.
- W2897846549 creator A5010810138 @default.
- W2897846549 creator A5018743654 @default.
- W2897846549 creator A5029196683 @default.
- W2897846549 creator A5029545881 @default.
- W2897846549 creator A5034911068 @default.
- W2897846549 creator A5045281711 @default.
- W2897846549 creator A5055591728 @default.
- W2897846549 creator A5064280092 @default.
- W2897846549 creator A5071857504 @default.
- W2897846549 creator A5072467824 @default.
- W2897846549 creator A5072902637 @default.
- W2897846549 creator A5087058809 @default.
- W2897846549 date "2018-10-01" @default.
- W2897846549 modified "2023-09-28" @default.
- W2897846549 title "Neoadjuvant therapy for esophageal adenocarcinoma: A propensity score-matched comparison of paclitaxel and carboplatin chemoradiotherapy with cisplatin and 5-fluoruracil-based chemo- or chemoradiotherapy" @default.
- W2897846549 doi "https://doi.org/10.1093/annonc/mdy282.015" @default.
- W2897846549 hasPublicationYear "2018" @default.
- W2897846549 type Work @default.
- W2897846549 sameAs 2897846549 @default.
- W2897846549 citedByCount "0" @default.
- W2897846549 crossrefType "journal-article" @default.
- W2897846549 hasAuthorship W2897846549A5005797468 @default.
- W2897846549 hasAuthorship W2897846549A5010810138 @default.
- W2897846549 hasAuthorship W2897846549A5018743654 @default.
- W2897846549 hasAuthorship W2897846549A5029196683 @default.
- W2897846549 hasAuthorship W2897846549A5029545881 @default.
- W2897846549 hasAuthorship W2897846549A5034911068 @default.
- W2897846549 hasAuthorship W2897846549A5045281711 @default.
- W2897846549 hasAuthorship W2897846549A5055591728 @default.
- W2897846549 hasAuthorship W2897846549A5064280092 @default.
- W2897846549 hasAuthorship W2897846549A5071857504 @default.
- W2897846549 hasAuthorship W2897846549A5072467824 @default.
- W2897846549 hasAuthorship W2897846549A5072902637 @default.
- W2897846549 hasAuthorship W2897846549A5087058809 @default.
- W2897846549 hasBestOaLocation W28978465491 @default.
- W2897846549 hasConcept C121608353 @default.
- W2897846549 hasConcept C126322002 @default.
- W2897846549 hasConcept C141071460 @default.
- W2897846549 hasConcept C143998085 @default.
- W2897846549 hasConcept C17923572 @default.
- W2897846549 hasConcept C2776694085 @default.
- W2897846549 hasConcept C2778239845 @default.
- W2897846549 hasConcept C2778292576 @default.
- W2897846549 hasConcept C2778424827 @default.
- W2897846549 hasConcept C2781182431 @default.
- W2897846549 hasConcept C2781451048 @default.
- W2897846549 hasConcept C530470458 @default.
- W2897846549 hasConcept C71924100 @default.
- W2897846549 hasConcept C90924648 @default.
- W2897846549 hasConceptScore W2897846549C121608353 @default.
- W2897846549 hasConceptScore W2897846549C126322002 @default.
- W2897846549 hasConceptScore W2897846549C141071460 @default.
- W2897846549 hasConceptScore W2897846549C143998085 @default.
- W2897846549 hasConceptScore W2897846549C17923572 @default.
- W2897846549 hasConceptScore W2897846549C2776694085 @default.
- W2897846549 hasConceptScore W2897846549C2778239845 @default.
- W2897846549 hasConceptScore W2897846549C2778292576 @default.
- W2897846549 hasConceptScore W2897846549C2778424827 @default.
- W2897846549 hasConceptScore W2897846549C2781182431 @default.
- W2897846549 hasConceptScore W2897846549C2781451048 @default.
- W2897846549 hasConceptScore W2897846549C530470458 @default.
- W2897846549 hasConceptScore W2897846549C71924100 @default.
- W2897846549 hasConceptScore W2897846549C90924648 @default.
- W2897846549 hasLocation W28978465491 @default.
- W2897846549 hasLocation W28978465492 @default.
- W2897846549 hasOpenAccess W2897846549 @default.
- W2897846549 hasPrimaryLocation W28978465491 @default.
- W2897846549 hasRelatedWork W1481820868 @default.
- W2897846549 hasRelatedWork W151172257 @default.
- W2897846549 hasRelatedWork W2348069219 @default.
- W2897846549 hasRelatedWork W2382328728 @default.
- W2897846549 hasRelatedWork W2471989939 @default.
- W2897846549 hasRelatedWork W3095199482 @default.
- W2897846549 hasRelatedWork W3144473405 @default.
- W2897846549 hasRelatedWork W4226023057 @default.
- W2897846549 hasRelatedWork W4302319510 @default.
- W2897846549 hasRelatedWork W4310754094 @default.
- W2897846549 hasVolume "29" @default.
- W2897846549 isParatext "false" @default.
- W2897846549 isRetracted "false" @default.
- W2897846549 magId "2897846549" @default.
- W2897846549 workType "article" @default.